Although pharmacy benefit managers say they are supportive of efforts to increase the availability and use of biosimilar alternatives to common high-cost prescription drugs, the Association for Accessible Medicines’ (AAM) Biosimilars Council released a new analysis showing that health plans and patients have missed out on up to $6 billion in savings related to biosimilars for the blockbuster drug Humira due to rebate schemes by PBMs.